Vaxcyte News and Activities
Presence
Vaxcyte develops vaccines for bacterial infectious diseases. Its main products are vaccine candidates and research services for healthcare providers, public health programs, and patients who need better disease prevention.
Vaxcyte products and services overview:
- Vaccine candidates
- Pneumococcal vaccines
- Shingles vaccines
- Research services
Revenue: ~$0 million
Employees: 300
Headquarters: San Carlos, United States (USA)
Vaxcyte is one of the...
Vaxcyte is a company listed under the stock ticker PCVX (US).
Executives
View the org chart displaying its 44 main executives
Most searched biographies at Vaxcyte
- Grant Pickering, President, Chief Executive Officer and Director
- Annie Drapeau, Director
- Carlos Paya, Chairman of the Board
Popular executive movements at Vaxcyte
- Moncef Slaoui has joined the company as Director (posted on June 24 2026).
- Jacks Lee, Director, has left the company (posted on June 24 2026).
- Guy Hagen, who was Director, Clinical Quality Assurance, is promoted to Senior Director, Clinical Quality Assurance (posted on April 7 2026).
Create your alert
to follow the executive moves at Vaxcyte.
Biotechnology
Vaxcyte has 2,413 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).
Popular M&A news in Biotechnology
- Ollin Biosciences has just announced a $330 Million fundraising (posted on June 24 2026).
- RQ Biotechnology has just announced a $86 Million fundraising (posted on June 24 2026).
- Boundless Bio has filed its IPO. Its stock ticker will be AATD. (posted on June 23 2026).
Popular contacts in Biotechnology
News
Press releases by Vaxcyte
- Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults - Vaxcyte, Inc.
- Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update - Vaxcyte, Inc.
- Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference - Vaxcyte, Inc.
- Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults - Vaxcyte, Inc.
- Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate - Vaxcyte, Inc.
- Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Vaxcyte, Inc.
- Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines - Vaxcyte, Inc.
- Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 - Vaxcyte, Inc.
- Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - Vaxcyte, Inc.
- Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit - Vaxcyte, Inc.
- View more press releases Close
Social media about Vaxcyte
- Vaxcyte on Wikipedia, Google News & Yahoo Finance
- Vaxcyte on LinkedIn, X (Twitter) & YouTube
